This study aims to evaluate in clinical practice the efficacy and safety of remdesivir in patients admitted for COVID-19
Keywords: Antivirals; COVID-19; outcome; remdesivir.

Description of the Study:
- Title: Real-life use of remdesivir in hospitalized patients with COVID-19.
- Principal Investigators: Carolina Garcia-Vidal, Fernanda Meira, Alberto Cózar-Llistó, Gerard Dueñas, Pedro Puerta-Alcalde, Nicole Garcia-Pouton, Mariana Chumbita, Celia Cardozo, Marta Hernandez-Meneses, Rodrigo Alonso-Navarro, Verónica Rico, Daiana Agüero, Marta Bodro, Laura Morata, et al.
- Centres of Implementation: Hospital Clínic of Barcelona.
- Study Population: Patients hospitalised for more than 48 hours with severe COVID-19.
- Study Type: Observational cohort study.
- Design: A total of 123 of the 242 patients admitted with COVID-19 received remodivir.
- Methods: A descriptive study was conducted of all patients admitted for ≥48 hours with confirmed COVID-19 who received remdesivir between 1 July and 30 September 2020.
Objectives of the Study:
Principal Objective: Controversial results have been reported on the efficacy of remdesivir, so the aim of this study is to report the real-life experience with the use of remdesivir since its availability in Spain.
More about this Study:
Conclusions: In their actual experience, the use of remdesivir in hospitalised patients with COVID-19 was associated with a low mortality rate and a good safety profile.
Scientific Context: On May 1st, 2020, remdesivir received Food and Drug Administration (FDA) emergency use authorization for hospitalized patients with COVID-19 and was officially approved on October 22nd, 2020. Initial clinical trials using a control arm demonstrated the superiority of remdesivir in terms of clinical status improvement at day 28 or at day 11; however, initial clinical trials performed in China and a recent report from the Solidarity trial did not prove that remdesivir had no benefit. Different outcomes and the potential influence of when remdesivir was administered after symptom onset could explain the apparently controversial results in the aforementioned trials.